Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.

Abstract

The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.

• Authors: Zeruesenay Desta, Roseann S Gammal, Li Gong, Michelle Whirl-Carrillo, Aditya H Gaur, Chonlaphat Sukasem, Jennifer Hockings, Alan Myers, Marelize Swart, Rachel F Tyndale, Collen Masimirembwa, Otito F Iwuchukwu, Sanika Chirwa, Jeffrey Lennox, Andrea Gaedigk, Teri E Klein, David W Haas
• Journal: Clinical pharmacology and therapeutics (Clin Pharmacol Ther) Vol. 106 Issue 4 Pg. 726-733 (10 2019) ISSN: 1532-6535 [Electronic] United States
• PMID: 31006110 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Systematic Review)
• Copyright: © 2019 The Authors Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics.

Chemical References

• Alkynes
• Anti-HIV Agents
• Benzoxazines
• Cyclopropanes
• CYP2B6 protein, human
• Cytochrome P-450 CYP2B6
• efavirenz

Topics

• Alkynes
• Anti-HIV Agents (pharmacology)
• Benzoxazines (pharmacology)
• Cyclopropanes
• Cytochrome P-450 CYP2B6 (genetics)
• HIV Infections (drug therapy, genetics)
• HIV-1
• Humans
• Pharmacogenetics
• Pharmacogenomic Testing (methods)
• Practice Guidelines as Topic